Chemokine N-terminal deletion mutations

Details Chemokine N-terminal deletion mutations Chemokine N-terminal deletion mutations

1995-05-31

1998-04-14

Degen, Nancy

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

424 851, 514 12, 514 21, 530351, 530395, 530402, 530409, C07K 1452, C08H 100, A61K 3819, A61K 4505

Patent

active

057391033

ABSTRACT:
The invention relates to mutant chemokines and pharmaceutical compositions thereof, wherein the mutant inhibits the corresponding endogenous chemokine from binding or activating a responsive receptor. The claimed mutant chemokines can be administered to a patient for the treatment or prophylaxis of a chemokine-mediated disease. The invention further relates to isolated DNAs encoding the mutant chemokines, vectors and recombinant host cells containing the same.

REFERENCES:
patent: 5459128 (1995-10-01), Rollins et al.
Zhang, Y. et al., "Structure/Activity Analysis of Human Monocyte Chemoattractant Protein-1 by Mutagenesis," J. Biol. Chem., 269(22):15918-15924 (Jun. 3, 1994).
Moser, B. et al., "Interleukin-8 Antagonists Generated by N-Terminal Modification," J. Biol. Chem., 268(10):7125-7128 (Apr. 1993).
Gong, J-H et al., "Antagonist of Monocyte Chemoattractant Protein-1 by Modification of the Functionally Critical N-terminal Residues," J. Exp. Med., 181:631-640 (Feb. 1995).
Rollins, Barrett et al., "Recombinant Human MCP-1/JE Induces Chemotaxis, Calcium Flux and Respiratory Burst in Human Monocytes," Blood, 78(4):1112-1116 (1991).
Prickett, K.S. et al., "A Calcium-dependent Antibody for Identification and Purification of Recombinant Proteins," Biotechniques, 7(6):580-589 (1989).
Koch, A.E. et al., "Enhanced production of chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms," Am. J. Pathol., 142(s):1423-1431 (May 1993).
Schnitzel, Wolfgang et al., "Monomer-dimer equilibria of interleukin-8 and neutrophil-activating peptide 2. Evidence of IL-8 binding as a dimer and oligomer to IL-8 receptor B," J. Leukocyte Biol., 55:763-770 (1994).
Clark-Lewis, Ian et al., "Structure-activity relationships of chemokines," Journal of Leukocyte Biology, 57(5):703-711 (1995).
Gong, Jiang-Hong et al., "RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors," Journal of Biological Chemistry, 271(18):10521-10527 (1996).
Zhang, Yujun and Rollins, Barrett J., "A Dominant Negative Inhibitor Indicates that Monocyte Chemoattractant Protein 1 Functions as a Dimer," Molecular and Cellular Biology, 15(9):4851-4855 (1995).

Affiliated with

Also associated with

Rating

Chemokine N-terminal deletion mutations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chemokine N-terminal deletion mutations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine N-terminal deletion mutations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-634559